Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.72 +0.58 (+0.59%)
Official Closing Price Updated: 4:10 PM EST, Jan 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,110,715
Open 98.77
Bid (Size) 99.77 (2)
Ask (Size) 99.90 (1)
Prev. Close 99.14
Today's Range 98.42 - 100.33
52wk Range 94.48 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+0.55%
+0.55%
1 Month
-3.27%
-3.27%
3 Month
-8.17%
-8.17%
6 Month
-20.72%
-20.72%
1 Year
-15.05%
-15.05%

More News

Read More
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Via Benzinga
NYSE:MRK: good value for what you're paying.
Via Chartmill
2 High-Yield Dividend Stocks to Buy Early in 2025
Via The Motley Fool
2 Reasons to Sell Merck Stock and 1 Reason to Buy
Via The Motley Fool
Not A Year For The 2024 Dogs Of The Dow
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Dissecting Our Discipline
Via Talk Markets
Topics Stocks / Equities
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Via Benzinga
Topics Stocks
Exposures US Equities
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Via Benzinga
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
Via Talk Markets
Topics ETFs Stocks / Equities
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Via Benzinga
Is Merck the Next Big Weight-Loss Stock?
Via The Motley Fool
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
Via The Motley Fool
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued?
Via Talk Markets
Topics Stocks / Equities
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
From Merck & Co., Inc.
Via Business Wire
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.